First and Second Generation Recombinant Factor VIII Concentrates in Previously Untreated Patients: Recovery, Safety, Efficacy, and Inhibitor Development

ABSTRACT

The first of the prospective multicenter studies in previously untreated patients (PUPs) with a recombinant factor VIII (FVIII) concentrate began in January 1989. Over the past 11 years, PUP studies have amassed a great deal of information concerning safety, efficacy, and inhibitor development of the two ``first-generation'' recombinant (r) FVIII concentrates (Kogenate℗ and Recombinate℗) and of two ``second-generation'' products (ReFacto℗ and Kogenate FS℗, which is formulated with sucrose rather than with albumin). Each of these products has proved to be safe, effective, and well-tolerated. Side effects have been rare and mild in nature. There have been no clinical reactions to hamster or murine proteins. During the course of the multinational PUP trials with Kogenate, Recombinate, and ReFacto, inhibitors developed in 29.7, 31, and 33%, respectively, of severely affected PUPs. Half of these were high titer and half were low titer. In each of these trials, several inhibitors were transient. PUPs and minimally treated patients (MTPs) in the Kogenate SF trial have not been followed long enough to determine the incidence of inhibitor development; however, the product appears to be safe and effective. Following demonstration of safety and efficacy with each rFVIII concentrate in previously treated patients with hemophilia A, studies in PUPs began. In general, the prospective trials in PUPs with each recombinant product were conducted similarly, allowing comparison of data. This article is intended to provide a review of the experience with both first- and second-generation rFVIII products in the prospective clinical trials in PUPs.

KEYWORDS

Previously untreated patient - rFVIII - inhibitor antibodies to FVIII - safety trials - second-generation rFVIII preparations

REFERENCES

• 1 Schwartz R S, Abildgaard C F, Aledort L M. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.  N Engl J Med . 1990;  323 1800-1805
• 2 Lusher J M, Arkin S, Abildgard C F, Schwartz R D. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. The Kogenate Previously Untreated Patient Study Group.  N Engl J Med . 1993;  328 453-459
• 3 Lusher J M, Arkin S, Abildgaard C F, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy and inhibitor development after seven study years. The Kogenate PUP Study Group (Abst PD-664).  Thromb Haemost . 1997;  (Suppl) 162
• 4 Rothschild C, Laurian Y, Satre E P. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance.  Thromb Haemost . 1998;  80 779-783
• 5 Bray G L, Gomperts E D, Courter S. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A.  Blood . 1994;  83 2428-2435
• 6 Gruppo R, Bray G L, Schroth P, Perry M, Gomperts E D. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): a 6.5 year update. The Recombinate PUP Study Group (Abst PD-663).  Thromb Haemost . 1997;  (Suppl) 162
• 7 Brown D L, Bray G L, Scharrer I. Transient inhibitors in patients with hemophilia A (Abst 1804).  Thromb Haemost . 1999;  (Suppl) 573
• 8 Mikaelsson M, Eriksson B, Lind P. Manufacturing and characterization of a new B-domain deleted recombinant factor VIII, r-VIII SQ (Abst).  Thromb Haemost . 1993;  69 1205
• 9 Lusher J M. Recombinant clotting factor concentrates.  Baillieres Clin Haematol . 1996;  9 291-303
• 10 Mikaelsson M, Oswaldsson U, Sandberg H. Influences of phospholipid on the assessment of factor VIII activity.  Haemophilia . 1998;  4 646-650
• 11 Fijnvandraat K, Berntorp E, ten Cate W J. Recombinant B-domain deleted FVIII (rVIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.  Thromb Haemost . 1997;  77 298-302
• 12 Barrowcliffe T W, Rant S, Hubbard A R. Discrepancies in potency assessment of recombinant FVIII concentrates.  Haemophilia . 1998;  4 634-640
• 13 Berntorp E. Second generation, B-domain deleted recombinant factor VIII.  Thromb Haemost . 1997;  78 256-260
• 14 Lusher J M, Gringeri A, Hann I, Rodriguez D. Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant FVIII (BDD rFVIII) (Abst 1037).  Blood . 1999;  94(Suppl 1) 23A
• 15 Lusher J M, Kreuz W, Gazengel C. Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rFVIII concentrate formulated with sucrose (Abst 1050).  Blood . 1999;  94(Suppl 1) 237A
• 16 Verbruggen B, Novakova I, Wessels H. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: Improved specificity and reliability.  Thromb Haemost . 1995;  73 247-251
• 17 Ehrenforth S, Kreuz W, Scharrer I. Incidence of development of factor VIII and factor IX inhibitors in haemophilias.  Lancet . 1992;  339 594-598
• 18 Scharrer I, Bray G L, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates.  Haemophilia . 1999;  5 145-154
• 19 Rosendaal F R, Nieuwenhuis H K, van den Berg M H. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group.  Blood . 1993;  81 2180-2186
• 20 Peerlinck K, Arnout J, Gilles J G. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.  Thromb Haemost . 1997;  77 80-86